3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Pancreatic Neoplasms
18
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Gastric Adenocarcinoma
1
Gallbladder Cancer Unresectable
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Brain Neoplasms
1
Anal Cancer Metastatic
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
130-nm albumin-bound paclitaxel
×
30 days
×
Clear all
NCT06841354
2026-05-29
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,000 enrolled
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled